Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CN¥ 27.76
Key Takeaways
Risk factor
Meaningful price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Guangzhou LBP Medicine Science & Technology Co., Ltd. engages in the research, development, and production of pathological diagnosis products in China. It offers pathological diagnostic reagents and ancillary equipment, including liquid-based cytology, such as gynecological series, non-gynecological series, and equipment; fluorescence in situ hybridization products for various applications in breast, bladder, lung, cervical, prostate, and...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is overpriced on P/E, 'expensive' on EV/EBITDA
Data is available to registered users only
Buy
Sell